Precision ALS drug startup wins funding from Amgen and Mitsubishi Tanabe

A new biotech startup founded by stem cell specialists from Harvard has won backing from Amgen Ventures, Alexandria Venture Investments and the investment arm of Mitsubishi Tanabe (TYO: 4508) in its goal to find a cure for amyotrophic lateral sclerosis (ALS).

QurAlis Corporation, which is headquartered on the East Coast on the USA, is focused on finding targeted treatments for ALS patients.

The firm notes that “recent insights from genetics and new biomarkers show that ALS is not one disease, but a spectrum of disorders with varying underlying mechanisms.” QurAlis scientists believe that, “like cancer, each ALS subtype needs to be treated with precision therapies.”